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Abstract
Background: Hallucinations occur in 20–40% of PD patients and have been associated with
unfavorable clinical outcomes (i.e., nursing home placement, increased mortality). Hallucinations,
like other non-motor features of PD, are not well recognized in routine primary/secondary clinical
practice. So far, there has been no instrument for uniform characterization of hallucinations in PD.
To this end, we developed the University of Miami Parkinson's disease Hallucinations
Questionnaire (UM-PDHQ) that allows comprehensive assessment of hallucinations in clinical or
research settings.
Methods: The UM-PDHQ is composed of 6 quantitative and 14 qualitative items. For our study
PD patients of all ages and in all stages of the disease were recruited over an 18-month period. The
UPDRS, MMSE, and Beck Depression and Anxiety Inventories were used for comparisons.
Results and Discussion: Seventy consecutive PD patients were included in the analyses. Thirty-
one (44.3%) were classified as hallucinators and 39 as non-hallucinators. No significant group
differences were observed in terms of demographics, disease characteristics, stage, education,
depressive/anxiety scores or cognitive functioning (MMSE) between hallucinators and non-
hallucinators. Single mode hallucinations were reported in 20/31 (visual/14, auditory/4, olfactory/2)
whereas multiple modalities were reported in 11/31 patients. The most common hallucinatory
experience was a whole person followed by small animals, insects and reptiles.
Conclusion: Using the UM-PDHQ, we were able to define the key characteristics of hallucinations
in PD in our cohort. Future directions include the validation of the quantitative part of the
questionnaire than will serve as a rating scale for severity of hallucinations.
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Background
Hallucinations occur in 20–40% of Parkinson's disease
(PD) patients receiving symptomatic therapy [1].
Although potentially treatable by anti-parkinsonian drug
adjustments and the use of atypical antipsychotics [2],
hallucinations have been associated with unfavorable
clinical outcomes such as nursing home placement and
increased mortality [3,4].
Hallucinations, like other non-motor features of PD, are
not well recognized in routine clinical practice, either in
primary or in secondary care, and are frequently missed
during consultations [5]. Standardized PD rating scales
such as the Unified Parkinson's disease Rating Scale
(UPDRS) part I [6] have low sensitivity to detect halluci-
nations and other psychotic symptoms[7]. Symptom and
disease specific instruments such as the Parkinson's Psy-
chosis Rating Scale (PPRS), [8] the non-motor symptom
questionnaire (NMSQuest) [5] or the Parkinson's Dis-
ease-Psychosocial questionnaire (SCOPA-PS) [9] assess
hallucinations only in a few sub-items. Other PD specific
instruments that may offer a more detailed characteriza-
tion of hallucinations, such as the Rush Parkinson's Dis-
ease Behavioral Interview [10] are not easily administered
in the busy clinical settings and generic rating scales/ques-
tionnaires that were designed to address organic brain
psychosis and/or neuropsychiatric manifestations (ie the
Neuropsychiatric Inventory [11]) are of limited use in
characterizing PD-associated hallucinations.
To date there is no instrument that allows for a focused,
comprehensive assessment of the characteristics of hallu-
cinations in PD for the clinician or for use as a research
outcome measure. We therefore developed the University
of Miami Parkinson's disease Hallucinations Question-
naire (UM-PDHQ), a 20-item questionnaire to be used as
a screening instrument to assess hallucinations in PD.
This pilot study, part of an initiative begun at the Univer-
sity of Miami, Miller School of Medicine sought to quan-
tify the type and presence of hallucinations in a clinic
population while controlling for disease factors, depres-
sion, anxiety and medication.
Methods
The University of Miami Parkinson's disease 
Hallucinations Questionnaire (UM-PDHQ)
The UM-PDHQ is a 20-item clinician-administered ques-
tionnaire that is completed during a structured interview
(see Additional file 1). The 20 items were derived through
consultations with PD patients, caregivers, and a panel of
experts including 4 movement disorders specialists, 1 ger-
iatric psychiatrist, 3 neuropsychologists, 1 nurse specialist
and 1 neuro-opthalmologist. The core group met on a
monthly basis for a period of 6 months to produce a
working questionnaire and subsequent revisions were
made to improve ease of administration. Questions were
divided into two groups; a quantitative group that consists
of 6 questions (modality, frequency, duration, insight,
emotional burden) and a qualitative group that consists
of 14 questions. The first item is a gating question to
assess the presence or absence of hallucinations. It is
derived from modifications to item 3 of the UPDRS part I,
and item 14 of the non-motor symptom questionnaire
(NMSQuest) for PD [5]. The quantitative section of the
UM-PDHQ is currently being validated and is used only
for descriptive purposes as part of this study. The com-
plete questionnaire is presented in the Appendix.
Patients
For the purposes of our pilot study, PD patients of all ages
and in all stages of the disease were recruited. PD patients
diagnosed using the U.K. PD Brain Bank criteria [12] were
evaluated at the Department of Neurology, University of
Miami, Miller School of Medicine. A movement disorders
specialist evaluated degree of motor impairment by
means of the Unified Parkinson's disease rating scale
(UPDRS) [13], side of symptom onset, and a modified
Hoehn and Yahr rating [13] as part of a comprehensive
neurological examination. In patients with "on-offs",
"on" UPDRS scores were used in the analysis. Items
derived from the activities of daily living (ADL) (UPDRS
part II) and motor features (UPDRS part III) subscales
were used to determine PD subtype, according to the
method proposed by Jankovic and colleagues [14]. The
subtypes are referred to as tremor-dominant PD (TD) and
postural instability/gait-dominant (PIGD). No patients
had evidence of hallucinations as part of a drug-induced
toxic delirium or complication of a superimposed medical
illness. All patients were screened for mental function
using the Mini Mental State Examination (MMSE) [15].
Depressive symptomatology was assessed during the clin-
ical interview with a neuropsychologist and was objec-
tively measured with the Beck Depression Inventory –
Second Edition (BDI-II), a 21-item self-report question-
naire of depressive symptoms [16]. The BDI has been val-
idated for use in PD [17,18] and compares favorably with
other depression screening measures [19]. Patients were
evaluated for anxiety using the Beck Anxiety Inventory
(BAI) [20]. The UM-PDHQ, BDI and BAI were adminis-
tered by a trained clinical neuropsychologists blinded to
the results of the neurological examination and UPDRS.
Our local institutional review board approved this study.
Statistical analyses
Statistical analysis was performed using the SPSS for Win-
dows release 11.0 (SPSS Inc, Chicago, Ill., USA). Compar-
isons of continuous data were carried out using Mann-
Whitney U test for 2 samples or Kruskal-Wallis tests for
more samples. Categorical data were analyzed using Chi-
square with Yates corrected p-value or Fisher exact 2-tail pBMC Neurology 2008, 8:21 http://www.biomedcentral.com/1471-2377/8/21
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value. All significance tests were two-tailed and were con-
ducted at p < 0.05.
Results
Participant characteristics
Seventy consecutive PD patients (46 men and 24 women)
seen in our center were included in the analyses. Mean age
at study inclusion was 64.3 ± 10.2 years and mean age of
PD onset was 55.1 ± 12.1 years. Thirty seven (52.9%)
patients had right-side PD onset. Mean Hoehn and Yahr
disease stage was 2.5 ± 0.7, mean MMSE was 25.6 ± 4.5,
mean BDI-II total score was 16.3 ± 12.7 and mean BAI
score was 18.7 ± 11.5
Using the UM-PDHQ 31 (44.3%) patients were classified
as hallucinators and 39 were classified as non-hallucina-
tors. The UPDRS part I identified 26 (37.1%) and fail to
report hallucinations in 5 patients. Significant group dif-
ferences were not observed in terms of gender, age at
examination, age at PD onset, side of PD onset, PD dura-
tion, disease stage, education, depressive/anxiety scores or
overall cognitive functioning (MMSE) between hallucina-
tors and non-hallucinators (Table 1). However, UPDRS
total, part I, II and III scores were significantly higher in
hallucinators (Table 1). There were no differences in dis-
ease subtypes (TD vs PIGD) between hallucinators and
non-hallucinators (p = 0.1). There were no differences
between groups in use of antiparkinsonian medication (L-
dopa dose, DA, MAO-B inhibitors, anticholinergics,
COMT inhibitors) (Table 2). Five (16.1%) patients with
hallucinations were being treated with antipsychotics,
whereas none of the patients without hallucinations (0%)
were on antipsychotics (p = 0.01). The use of antidepres-
sants was similar between groups. Comparisons between
active and past hallucinators did not reveal statistical sig-
nificant results in any of the demographic and clinical
parameters tested.
Characteristics of hallucinators
Of the 31 patients more than half (56%) experienced hal-
lucinations once per week or more. The reported fre-
quency of hallucinations is presented in Figure 1.
Hallucinations were instantaneous (<1 sec) in 10
(32.3%), of medium duration (<10 sec) in 18 (58.1%)
Table 1: Demographics and phenotypic features of our patient population
Variable All patients Non Hallucinators N = 39 Hallucinators N = 31
Gender (%male) 46 (65.7%) 25 (64.1%) 21 (67.7%)
Age at onset in yrs (SD) 55.1 (12.1) 55.8 (11.8) 54.4 (12.5)
Age at exam in yrs (SD) 64.3 (10.2) 64.3 (10.5) 63.9 (10.0)
Range 39–84 44–83 39–84
Disease Duration in years (SD) 9.0 (5.4) 8.5 (5.3) 9.5 (5.6)
Hoehn and Yahr stage (SD) 2.5 (0.7) 2.4 (0.7) 2.5 (0.7)
(min-max) 1–5 1–5 1.5–4
Hoehn and Yahr 1 (%) 4 (5.7) 4 (10.3) 0
Hoehn and Yahr 1.5 (%) 5 (7.1) 3 (7.7) 2 (6.5)
Hoehn and Yahr 2 (%) 21 (30.0) 12 (30.8) 9 (29)
Hoehn and Yahr 2.5 (%) 23 (32.9) 12 (30.8) 11 (35.5)
Hoehn and Yahr 3 (%) 8 (11.4) 4 (10.3) 4 (12.9)
Hoehn and Yahr 4 (%) 8 (11.4) 3 (7.7) 5 (16.1)
Hoehn and Yahr 5 (%) 1 (1.4) 1 (2.6) 0
UPDRSI* 4.2 (2.7) 3.5 (2.3) 5.3 (2.9)
UPDRSII* 13.6 (7.5) 11.2 (5.9) 17.2 (8.2)
UPDRSIII* 22.1 (10.0) 19.1 (10.3) 26.1 (8.1)
Side of onset
Right 37 (52.9%) 21 (53.8%) 16 (51.6%)
Left 27 (38.6%) 16 (41.0%) 11 (35.5%)
Bilateral 5 (71.%) 2 (5.1%) 3 (9.7%)
Unknown 1 (1.4%) 0 1 (3.2%)
Education in yrs (SD) 13.0 (4.4) 12.8 (4.2) 13.2 (4.9)
MMSE score (SD) 25.6 (4.5) 26.1 (4.2) 25.0 (4.7)
(min-max) 10–30 14–30 10–30
BDI (SD) 16.3 (12.7) 15.1 (11.1) 17.9 (14.7)
BAI (SD) 18.7 (11.5) 16.5 (10.2) 21.5 (12.6)
*Statistically significant (p > 0.05)
Yrs: years, SD: Standard deviation, UPDRS: Unified Parkinson's disease rating scale, MMSE: Mini Mental State Exam, BDI: Beck's Depression 
Inventory, BAI: Beck's Anxiety InventoryBMC Neurology 2008, 8:21 http://www.biomedcentral.com/1471-2377/8/21
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and of prolonged duration (>10 sec) in 1 PD patient. Two
patients could not specify the duration of their experi-
ences. None of the hallucinators reported current eye dis-
ease other than corrected refractory problems. Two out of
31 (6.5%) patients reported that their hallucinations
resulted after alterations in their treatment. In patients
experiencing on-off motor fluctuations, hallucinations
were present more often during the on phase (13 during
on and 2 during off). Fifteen hallucinators (48.4%) were
classified in the TD group and 16 (51.6%) in the PIGD
group. Onset of hallucinations was sudden in the majority
of patients (21/31). Only 4 reported gradual onset and the
rest were not sure of onset type. Hallucinations were less
frequently associated with the light cycle (Figure 2).
When patients were questioned as to whether they
thought their hallucinations were real (non-retained
insight), 11 (35.5%) patients responded "no", 7 (25.5%)
thought that they were sometimes real, 10 (32.3%)
responded "yes" and the rest could not tell. Surprisingly,
there were no differences (p = 0.99) in the mean MMSE
scores between these groups (24.2 ± 5.2 vs 25.2 ± 5.0 vs
24.9 ± 4.7). None of the other parameters were signifi-
cantly different. In 13 (42%) patients hallucinations were
described as friendly/indifferent but in 18 (58%) some
measure of distress was reported (mild in 19.4%, moder-
ate in 16% and severe in 22.6%). Patients distressed by
hallucinations were more frequently (p = 0.02) on antide-
pressants (no distress: 2; 18.2% vs distress 9; 81.8%).
None of the other parameters tested reached significance
although BDI-II and BAI scores were higher in patients
admitting distress due to hallucinations (BDI-II 21.6 ±
15.9 and BAI 25.2 ± 15.7) versus patients without distress
(BDI-II 14.0 ± 12.7 and BAI 17.8 ± 7.6). Only 12/31
(38.7%) patients admitted that sensations experienced
during hallucinations were familiar.
Single mode hallucinations were reported in 20/31 (vis-
ual 14, auditory 4, olfactory 2) whereas multiple modali-
ties were reported in 11/31 patients. Frequencies of
different modalities are presented in Figures 3. Five
(16.1%) patients admitted that their visual experiences
were accompanied by sound, usually voices. Compari-
sons between patients with hallucinations in one versus
multiple modalities did not reveal statistical significant
results in any of the parameters tested. Seven patients
(22.5%) with hallucinations did not report a visual com-
ponent. All patients with non-visual hallucinations were
male versus 14/24 (58.3%) in the visual hallucinations
group (p = 0.04). Other comparisons between visual and
non-visual hallucinators did not reveal significant results
in the parameters tested.
Content of visual hallucinations is presented in Figure 4.
The most common hallucinatory experience was a whole
person followed by small animals, insects and reptiles.
Visual hallucinations were usually of normal size with
only 3 patients reporting size distortion. Eleven out of 24
patients (46%) experiencing visual hallucinations
Table 2: Medication profile
Group Non Hallucinators Hallucinators
N = 39 N = 31
L-dopa 38 (97.4%) 30 (96.8%)
Dopamine Agonist 25 (64.1%) 18 (58.1%)
Amantadine 9 (23.1%) 7 (22.6%)
Anticholinergics 4 (10.3%) 4 (12.9%)
COMT inhibitors 7 (17.9%) 4 (12.9%)
MAO-B inhibitors 2 (5.1%) 3 (9.7%)
Cholinesterase inhibitors 4 (10.3%) 1 (3.2%)
Antipsychotics* 0 5 (16.1%)
Antidepressants 12 (30.8%) 11 (35.5%)
*p = 0.01
Overall frequency of hallucinations Figure 1
Overall frequency of hallucinations.BMC Neurology 2008, 8:21 http://www.biomedcentral.com/1471-2377/8/21
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reported that their hallucinations were considered "achro-
matic". Only 2 reported transparent images. A selected
description of hallucinatory experiences is presented in
Table 3.
Discussion
Hallucinations in PD have received growing attention
since the introduction of chronic treatments of dopamine
restoration which increased their frequency from 5% in
the pre-L-dopa era [21-23] to around 40% in chronically
treated patients at least 3 years into their disease [1]. Hal-
lucinations may be considered a characteristic of α-synu-
cleinopathies, a group of diseases associated with
excessive accumulation of α-synuclein in the CNS that
includes PD, dementia with Lewy bodies and multiple
system atrophy [24,25] and a red flag for Lewy body
pathology [26].
Although there is an extensive literature in this area, lack
of consistency and standardization of assessment
approaches has significantly biased comparison data
across studies and made it difficult to conclude about
prevalence rates, content, classification, risk factors and
treatment outcomes [1]. Only recently a set of diagnostic
criteria for psychotic symptoms that include hallucina-
tions in PD, were proposed by a panel of NIH-sponsored
experts. This working group highlighted the lack of rele-
vant instruments/scales [27]. Few studies i.e. [28,29] have
used validated scales or structured interviews, including
the UPDRS I thought disorder subscale score [6] and the
Rush Parkinson's Disease Behavioral Interview [10]
respectively. Our study confirmed previous findings that
showed that the UPDRS thought disorders subscale is not
considered the most sensitive instrument to detect psy-
chotic symptoms in PD [7]. The Rush Behavioral inter-
view primarily assesses the severity of hallucinations of all
modalities focusing on frequency in the past month:
severity score: 0 = none, 1 = less than once weekly, 2 =
once or twice weekly, 3 = at least three times weekly and
does not ascertain detailed information about the type
and nature of hallucinations. Severe hallucinations are
defined as a score of 3. To this end we developed the UM-
PDHQ to systematically study hallucinatory experiences
in PD in an outpatient clinic setting.
Hallucinatory experiences/patient Figure 3
Hallucinatory experiences/patient. Columns represent individual patients and rows represent different hallucinatory 
modalities.
Frequency of hallucinations according to light cycle Figure 2
Frequency of hallucinations according to light cycle.BMC Neurology 2008, 8:21 http://www.biomedcentral.com/1471-2377/8/21
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The UM-PDHQ confirmed previous findings on the prev-
alence of hallucinations; the prevalence in our cohort
(44.3%) was similar to other clinic-based prospective
studies and somewhat higher than previously reported in
community studies [30,31]. Studies focusing on a single
hallucinatory modality, mainly visual [32,33], have con-
sistently reported lower prevalence of hallucinations as
they fail to consider auditory, olfactory, somatic and gus-
tatory modalities. Among hallucinators, the cumulative
percentage of reported non-visual modalities was 54.8%.
In PD, hallucinatory experiences tend to be present inter-
mittently, lasting seconds to minutes at a time [34]. Their
frequency can vary, but most studies register the presence
of hallucinations when they occur at least one time per
week. Often, they occur several times per day [27]. The
typical hallucinatory experience in our clinic-based cohort
was that of a non-threatening, familiar or unfamiliar
solid, real sized, colored or colorless human body that
appeared suddenly anytime during the day and disap-
peared a few seconds later. Little animals and insects were
also common. A variety of other non-typical hallucinatory
sensations were very frequently described. Therefore one
should not consider hallucinatory experiences in PD uni-
form. Simplistic classifications such as benign-malignant,
simple-complex or minor-major should be avoided until
a scaling method has been developed and validated. We
also found that hallucinations were unrelated to light
cycle in the majority of patients. Previous reports have
suggested that hallucinations tend to occur during times
of low ambient stimulation, most typically in the evening
or when the patient is alone in a quiet environment [27].
Hallucinations lacking a visual component were reported
in 7 out of 70 patients with an overall prevalence of 10%.
Several other systematic prospective studies have pointed
out the increased frequency of non-visual hallucinatory
modalities in PD [35,36]. Their content may vary consid-
erably [37,38]. Non-visual hallucinations may often con-
sist of whispers or music, as opposed to the threatening
voices reported in schizophrenia; however, some cases of
threatening auditory hallucinations have been reported in
PD [39]. Tactile, olfactory and gustatory hallucinations
have also been reported; however less commonly, and
they tend to co-occur with visual hallucinations [40,41].
There were no differences detected between hallucinators
and non-hallucinators in demographic and neuropsychi-
atric profiles. Confirming previous observations from our
group, hallucinations interfered with activities of daily liv-
ing and were related to more severe symptomatology as
measured by the UPDRS [32]. As expected, hallucinators
were more frequently prescribed antipsychotics. Although
cognitive impairment and dementia have been frequently
Table 3: Descriptions of hallucinatory experiences in Parkinson's 
disease
"I smell cleaning products"
"I see fragmented bodies"
"I hear conversations; usually people arguing"
"I hears voices"
"I see unfamiliar male faces; I also see little bears"
"I hear my parents' voices and "psst psst psst" sounds that remind me 
of a bird"
"I see people running, human silhouettes, dogs that make noises. I also 
hear voices"
"I occasionally think the telephone is ringing when it is not"
"I see a shadow and feel like someone is sitting on chest"
"I see my neighbor's children"
"I see shadows of people"
"I smell medicine"
"I see spider webs and a luminous ball"
"I smell gas"
Content of hallucinations Figure 4
Content of hallucinations.BMC Neurology 2008, 8:21 http://www.biomedcentral.com/1471-2377/8/21
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reported as risk factors for hallucinations in PD [31] no
such association (as measured by the MMSE score) was
detected in our study. Our results are in line with those of
another interview-based prospective study that found no
association between MMSE scores and hallucinations at
the conclusion of a 4-year study [29]. In our cohort loss of
insight regarding hallucinatory experiences was unrelated
to cognitive status. Loss of insight has been associated
with the "continuum hypothesis" that suggests a progres-
sion of psychotic symptoms from sleep disturbances to
hallucinatory experiences to full-blow psychosis [42].
However, our findings on insight and spontaneous remis-
sion of hallucinations in 9/31 (29%) of patients coupled
with lack of a REM behavior sleep disorder in some hallu-
cinators [43,44] suggest that this theory may not apply for
all patients. In using only the MMSE as our measure of
cognitive status, we did not examine particular cognitive
domains that may have differentiated hallucinators from
non-hallucinators. BDI scores and BAI scores were not sig-
nificantly different between hallucinators and non-hallu-
cinators. It is unclear from our data whether the higher
prevalence of antidepressant use among hallucinators
who were distressed by their hallucinations as compared
to those not distressed was either a contributor to or a
cause of the distress.
Our study has certain limitations; the UM-PDHQ in its
current form does not provide an overall score of severity
and is not a graded or rating instrument. Instead, it is a
screening tool designed to draw attention to the presence
of hallucinations and initiate further investigation. In our
study cognitive status was assessed using the MMSE which
is a brief screening measure that is known to be less sensi-
tive to subcortical functions [45]. However, examining the
relationship between cognitive decline and hallucinations
was beyond the scope of this pilot study. We are currently
collecting more detailed neuropsyhological data in a
larger cohort of patients to examine this important ques-
tion.
Conclusion
Using the UM-PDHQ during a structured interview we
were able to define in depth the key characteristics of hal-
lucinations in a pilot cohort of PD patients. Future direc-
tions include the validation of the questionnaire and the
development of a disease and symptom rating scale for
severity of hallucinations. The UM-PDHQ may be modi-
fied in the future as additional data become available.
Valid criteria for psychotic symptoms in PD combined
with disease specific questionnaires and scales may pro-
vide the necessary endpoints that meet regulatory needs
for future clinical trials on the subject.
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